Frequently Asked Questions
The market is segmented based on , By Indication (Acute Kidney Injury, Chronic Kidney Disease, End-Stage Renal Disease, Others), Treatment (Corticosteroids, ACE Inhibitors, Diuretics, Immunosuppressive Therapy, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
.
The Global Renal Disease Market size was valued at USD 96.72 USD Billion in 2021.
The Global Renal Disease Market is projected to grow at a CAGR of 5.5% during the forecast period of 2022 to 2029.
The major players operating in the market include Pfizer , AstraZeneca, BristolMyers Squibb Company, AbbVie., Dr. Reddy's Laboratories Ltd, Endo International plc, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Mylan N.V., Novartis AG, Lupin, Cipla , Aurobindo Pharma, Fresenius SE & Co. KGaA, Sanofi, Takeda Pharmaceutical Company Limited, F. HoffmannLa Roche Ltd, Abbott.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
